Form 4: RAPT Therapeutics Acquired by GSK for $58/Share

RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline LLC for $58.00 per share in cash, completing a tender offer and subsequent merger.

Summary

• RAPT Therapeutics, Inc. was acquired by GlaxoSmithKline LLC (Parent) through its wholly-owned subsidiary Redrose Acquisition Co. (Purchaser).
• The acquisition was completed via a tender offer at $58.00 per share in cash, without interest and subject to applicable withholding taxes.
• The merger became effective on March 3, 2026, with RAPT Therapeutics surviving as an indirect wholly-owned subsidiary of Parent.
• All outstanding Restricted Stock Units (RSUs) were cancelled and converted into the right to receive cash equal to the total number of shares issuable multiplied by the $58.00 Offer Price.
• All outstanding stock options were accelerated and fully vested immediately prior to the Effective Time.
• Stock options with an exercise price less than $58.00 were cancelled and converted into cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Offer Price over the exercise price.
• Stock options with an exercise price greater than $58.00 were cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for RAPT Therapeutics shareholders who received a cash premium for their shares, and for in-the-money option/RSU holders. The completion of the merger provides certainty and liquidity.

Positives

• Shareholders received $58.00 per share in cash for their common stock, providing liquidity and a premium.
• Restricted Stock Unit (RSU) holders received cash based on the $58.00 Offer Price.
• In-the-money stock option holders received cash for the intrinsic value of their options, with vesting accelerated.

Negatives

• Stock options with an exercise price greater than $58.00 were cancelled for no consideration, resulting in a loss for those holders.
• RAPT Therapeutics, Inc. is no longer an independent publicly traded company, removing its shares from public markets.

Future Outlook

The filing indicates the completion of the acquisition of RAPT Therapeutics by GlaxoSmithKline, meaning RAPT Therapeutics will operate as an indirect wholly-owned subsidiary of GSK. No independent future outlook for RAPT Therapeutics is provided.

Industry Context

StockSavvy.ai notes that this acquisition by GlaxoSmithKline aligns with the broader pharmaceutical industry trend of larger players acquiring smaller biotech firms to bolster their pipelines and intellectual property. This particular deal likely strengthens GSK's position in a specific therapeutic area, given RAPT's focus, and reflects ongoing consolidation pressures and strategic asset accumulation within the sector.

Comparison to Industry Standards

• The $58.00 per share offer price for RAPT Therapeutics represents a significant premium over its pre-announcement trading price, which is typical for biotech acquisitions. For example, Pfizer's acquisition of Seagen for $43 billion in 2023 represented a substantial premium, and Merck's acquisition of Prometheus Biosciences for $10.8 billion in 2023 also featured a significant premium, reflecting the high value placed on promising drug candidates and platforms.
• The treatment of equity awards, including the acceleration of vesting and cash-out of in-the-money options and RSUs, is standard practice in M&A transactions to ensure executive and employee alignment and compensation for their contributions leading up to the acquisition.
• The cancellation of out-of-the-money options for no consideration is also a common outcome in such transactions, as these options hold no intrinsic value at the acquisition price.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $58.00 per share in cash, providing liquidity and a premium for their investment.
• Employees (including option/RSU holders): Equity awards were cashed out or cancelled, providing immediate value for in-the-money awards and concluding their participation in the company's equity plan.
• Customers/Suppliers: Likely minimal immediate impact on operational relationships, as RAPT's business activities are now integrated under GSK's larger corporate structure.

Next Steps

• No specific future actions for the former RAPT Therapeutics as an independent entity are mentioned, as it is now a wholly-owned subsidiary of GSK.

Key Dates

Keywords

RAPT Therapeutics, GSK, GlaxoSmithKline, Merger, Acquisition, Tender Offer, Form 4, Beneficial Ownership, Stock Options, RSUs, Biotech Acquisition, Pharmaceutical M&A